Zynerba Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Armando Anido

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage	33.6%
CEO tenure	9yrs
CEO ownership	1.9%
Management average tenure	6.8yrs
Board average tenure	8.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Armando Anido's remuneration changed compared to Zynerba Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$633k	-US$35m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	US$2m	US$603k	-US$37m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$1m	US$585k	-US$51m
Sep 30 2020	n/a	n/a	-US$52m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$36m
Dec 31 2019	US$1m	US$568k	-US$33m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$2m	US$568k	-US$40m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$41m
Mar 31 2018	n/a	n/a	-US$37m
Dec 31 2017	US$2m	US$552k	-US$32m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$26m
Dec 31 2016	US$901k	US$536k	-US$23m

Compensation vs Market: Armando's total compensation ($USD1.88M) is above average for companies of similar size in the UK market ($USD348.42K).

Compensation vs Earnings: Armando's compensation has been consistent with company performance over the past year.

CEO

Armando Anido (65 yo)

9yrs

Tenure

US$1,881,402

Compensation

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Terri Sebree	President	9yrs	US$1.38m	1.18% $ 775.1k
James Fickenscher	CFO & VP of Corporate Development (Leave of Absence)	7.1yrs	US$1.26m	0.75% $ 491.5k
Kenneth Jones	VP, Corporate Controller & Interim CFO	6.6yrs	no data	0.17% $ 111.2k
Albert Parker	Chief Legal Officer & Corporate Secretary	1.7yrs	no data	0.45% $ 295.1k
Joseph Apostolico	Vice President of Human Resources	5.6yrs	no data	no data

6.8yrs

Average Tenure

59yo

Average Age

Experienced Management: 0M40's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Kenneth Moch	Independent Director	8.2yrs	US$107.50k	0.15% $ 98.5k
Daniel Kisner	Independent Director	8.2yrs	US$105.00k	0.15% $ 98.5k
Warren Cooper	Lead Independent Director	8.2yrs	US$135.00k	0.15% $ 98.5k
John Butler	Independent Director	5.5yrs	US$102.50k	0.16% $ 105.0k
William Federici	Independent Director	8.2yrs	US$110.00k	0.15% $ 98.5k
Steven Siegel	Member of Scientific Advisory Board	no data	no data	no data
Randi Hagerman	Member of Scientific Advisory Board	8yrs	no data	no data
Elizabeth Berry-Kravis	Member of Scientific Advisory Board	no data	no data	no data
Nicole Tartaglia	Member of Scientific Advisory Board	7yrs	no data	no data
Pamela Stephenson	Independent Director	4.7yrs	US$100.00k	0.15% $ 98.5k
Craig Erikson	Member of Scientific Advisory Board	no data	no data	no data

8.2yrs

Average Tenure

65yo

Average Age

Experienced Board: 0M40's board of directors are considered experienced (8.2 years average tenure).

Zynerba Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age